论文部分内容阅读
采用化学沉淀法制备 Fe3O4超微磁粉 ,以聚 (5 ,5 -二甲 -三亚甲基碳酸酯 -共 -三亚甲基碳酸酯 )为膜材 ,包裹纳米级 Fe3O4磁粉 ,制备出丝裂霉素 -聚碳酸酯磁性微球。研究了此微球制剂体外对肝癌细胞的细胞毒作用 ,并在外加磁场的作用下对人裸鼠肝癌模型进行了靶向治疗实验。结果表明 ,该磁性微球具有良好的磁响应性能 ,体外 40 0 0 GS磁场下动作距离为 2 4cm / min,体外对肝癌细胞 Bel- 740 2有较强的细胞毒作用 ,裸鼠人肝癌模型靶向治疗实验显示 ,在肿瘤部位 5 0 0 0 GS条件下 ,静脉用药 3次即有明显抑制肿瘤生长作用 ,其 4周瘤重抑制率为 5 7.94% ,明显高于游离药物组 (2 3.37% ,P<0 .0 0 1)和无磁药物微球组 (2 4.19% ,P<0 .0 0 1)。本实验为肝癌的靶向治疗提供了一种可能的新剂型 ,有较好的临床应用前景。
Fe3O4 ultrafine magnetic powder was prepared by chemical precipitation method and poly(5,5-dimethyl-trimethylene carbonate-co-trimethylene carbonate) was used as a membrane material to encapsulate nanoscale Fe3O4 magnetic powder to prepare mitomycin. - Polycarbonate magnetic microspheres. The cytotoxicity of this microsphere preparation on hepatocellular carcinoma cells in vitro was studied, and targeted therapy experiments on human hepatoma models of nude mice were performed under the external magnetic field. The results show that the magnetic microspheres have good magnetic response performance. The action distance is 4 4 cm / min in vitro with a 400 GS magnetic field. It has a strong cytotoxic effect on hepatoma cells Bel-740 2 in vitro and a human hepatoma model in nude mice. Targeted therapy showed that tumor growth was significantly inhibited by intravenous administration of the drug at the tumor site of 500 GS for 3 times. The tumor weight inhibition rate at 4 weeks was 5 7.94%, which was significantly higher than that of the free drug group (2 3.37). %, P <0. 0 0 1) and non-magnetic drug microspheres (2 4.19%, P <0.01). This experiment provides a possible new dosage form for the targeted treatment of liver cancer, and has a good clinical application prospects.